> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Guide on Acute Myeloid Leukemia Therapies
- URL: https://www.fdaweb.com/guide-on-acute-myeloid-leukemia-therapies/
- Published: 2022-10-17T12:00:00.000Z
- Updated: 2026-09-14T18:03:21.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5152986

FDA has made available a final guidance entitled “Acute Myeloid Leukemia (AML): Developing Drugs and Biological Products for Treatment.” The [document](https://www.fda.gov/media/162362/download?ref=fdaweb.com) provides the agency’s current thinking on the overall development program and clinical trial designs for drugs to support an indication for treating AML, including indications limited to an individual phase of treatment (e.g., maintenance, transplantation preparative regimen, etc.).

The guidance discusses previous standard treatments for AML, including cytotoxic chemotherapy for induction and consolidation with or without post-remission allogeneic hematopoietic stem cell transplantation. “However, many patients with AML who had just mild pathological or age-related organ impairment at diagnosis were considered to have too high a risk of life-threatening or fatal organ toxicity from such intensive therapy and therefore were offered only palliative treatments or no treatment at all,” it says. “New classes of drugs, including drugs that target the specific pathogenetic mutations or a disordered epigenome, are being developed as alternatives to cytotoxic drugs for the treatment of AML.”

The guidance further opines that in some cases, these newer approaches may prolong survival without a prospect for cure, “but extending survival may be a meaningful benefit for patients who would live for only weeks if left untreated. Inducing temporary control of disease with minimal treatment burden and palliation of symptoms are two additional outcomes that might also be considered meaningful in certain circumstances… The expansion of treatment intent, broadening of the intended population, and development of a wide range of new drug classes as alternatives to cytotoxic drugs contribute substantially to the complexity of clinical development programs for new drugs for AML. This guidance addresses these considerations and provides recommendations regarding the design and conduct of clinical trials and the types of supporting data that would facilitate efficient development of drugs for the treatment of AML.”